Assessment of safety and antihypertensive efficacy of a cardioselective beta-blocker nebivolol in patients with hypertension and concomitant chronic obstructive bronchitis

Safety, tolerability and antihypertensive efficacy of a cardioselective beta-blocker nebivolol was studied in 30 patients with mild and moderate hypertension and concomitant stage I chronic obstructive bronchitis. Nebivolol (5 mg/day) was given for 1 month; in 5 patients complementary hydrochlorothi...

Full description

Saved in:

Bibliographic Details
Published in:	Kardiologiia Vol. 42; no. 11; p. 36
Main Authors:	Iakushin, S S, Okorokov, V G, Liferov, R A, Fomina, V A, Ivanova, G O
Format:	Journal Article
Language:	Russian
Published:	Russia (Federation) 2002
Subjects:	Adrenergic beta-Antagonists - adverse effects Adrenergic beta-Antagonists - therapeutic use Adult Benzopyrans - adverse effects Benzopyrans - therapeutic use Bronchitis, Chronic - complications Ethanolamines - adverse effects Ethanolamines - therapeutic use Humans Hypertension - complications Hypertension - drug therapy Male Middle Aged Nebivolol
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Safety, tolerability and antihypertensive efficacy of a cardioselective beta-blocker nebivolol was studied in 30 patients with mild and moderate hypertension and concomitant stage I chronic obstructive bronchitis. Nebivolol (5 mg/day) was given for 1 month; in 5 patients complementary hydrochlorothiazide (12.5 mg/day) was required for sufficient antihypertensive effect. Nebivolol was well tolerated (only 1 patient complained of head ache), did not cause worsening of bronchitis and spirometric parameters, exerted no cardiodepressive action, and did not induce apparent disturbances of metabolism.
ISSN:	0022-9040